预约演示
更新于：2025-05-24
Ergocalciferol
维生素D2
更新于：2025-05-24
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H44O |
InChIKeyMECHNRXZTMCUDQ-RKHKHRCZSA-N |
CAS号50-14-6 |
关联
100
项与 维生素D2 相关的临床试验ChiCTR2400094475
The Effect of Vitamin D2 Intervention on Thyroid Antibodies and 25-Hydroxyvitamin D Levels in Patients with Chronic Lymphocytic Thyroiditis
NCT06642441
Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer
CTRI/2024/11/076492
Impact of Ergocalciferol-enhanced Mushrooms on Vitamin D Concentration and Insulin Resistance: A Randomized, Single-Blind Study in Vitamin D Deficient, Overweight, or Obese Young Adults in Bangalore, India. - NIL
100 项与 维生素D2 相关的临床结果
登录后查看更多信息
100 项与 维生素D2 相关的转化医学
登录后查看更多信息
100 项与 维生素D2 相关的专利（医药）
登录后查看更多信息
5,281
项与 维生素D2 相关的文献（医药）2025-07-01JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Contribution of different vitamin D forms and fortified foods to vitamin D intake in Europe: A narrative review
Review
作者: Bruins, Maaike J
In the current narrative review, the bioavailability of the main vitamin D forms is evaluated. The mean intakes and main contributing forms of vitamin D in the European diet are estimated, as well as the major contributing dietary sources. The literature is reviewed for studies reporting on the proportion of users and non-users of fortified food with vitamin D intakes below reference intakes. In addition, the availability of vitamin D-fortified prepackaged retail products and fortification levels in the European market is assessed. Previously, vitamins D2 and D3 forms were considered the primary forms in the diet. Recent analytical methods suggest that dietary 25(OH)D3, when adjusted for higher bioequivalence, significantly contributes to total vitamin D intakes. When also considering 25(OH)D3 from foods, the estimated vitamin D intake from an average European diet was 3.8 µg/d of total Vitamin D Equivalents: vitamin D3, vitamin D2 and 25(OH)D3, contributing about 71 %, 2 %, and 27 %, respectively. Animal foods, fortified fats and spreads contributed most to total intakes. Literature suggests that 94-100 % of Europeans aged ≥ 13 y fail to meet the vitamin D reference intake of 10 µg/d. About 98-100 % of vitamin D-fortified food users and 99-100 % of non-users in the UK and Netherlands consumed less than 10 µg/d of vitamin D. About 1.2 % of prepackaged foods and drinks were voluntary fortified with vitamin D, margarine and plant-based drinks providing most of the daily vitamin D. Encouraging fortification and other strategies may support closing the gap between current and recommended vitamin D intakes.
2025-06-01HEARING RESEARCH
Drug-induced hearing loss: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Article
作者: Du, Qian ; Zhu, Bin ; Zhao, Zhigang ; Dong, Jie ; Li, Dongxuan ; Shi, Yanfeng ; Wu, Tingxi ; Wang, Peng
Drug-induced hearing loss (DIHL) is highly prevalent, but a comprehensive picture of ototoxicity associated with drugs are still lacking. In order to comprehensively summarize the hearing safety information of current drugs, we used the real-world data from 2004 to 2023 in the FDA Adverse Event Reporting System (FAERS) database to integrate the reported ototoxicity information of drugs and applied disproportionality analysis to evaluate the hearing impairment risk induced by drugs. A total of 108,435 adverse event (AE) reports of hearing impairment were extracted from the FAERS database, involving 1300 reported culprit-drugs. On the whole, acetylsalicylic acid was the most frequently reported potential ototoxic drug, followed by levothyroxine sodium, adalimumab, omeprazole, and ergocalciferol. Immunosuppressants was the most frequently reported drug class, followed by analgesics, psychoanaleptics, agents acting on the renin-angiotensin system, and antineoplastic agents. In risk signal detection, 432 of 1300 drugs exhibited potential ototoxic risk, in which tafenoquine showed the strongest statistical correlation with hearing impairment, followed by teprotumumab, amyl nitrite, potassium iodide, and paromomycin. Among main drug classes, antibacterials for systemic use was the drug class contained the maximum number of drugs with positive ototoxic risk signals, followed by psychoanaleptics, agents acting on the renin-angiotensin system, antineoplastic agents, and analgesics. In conclusion, our study summarized a comprehensive drug list containing 1300 reported potential ototoxic drugs in the FAERS database and profiled their ototoxicity risk characteristic from the aspect of reporting frequency and risk signal strength, which can provide reference for clinical medical staff to strengthen monitoring and management of DIHL.
2025-06-01Sugar Tech
An Assessment of Physico-Chemical Properties, Micronutrients, Polyphenolic Profile, and Antioxidant Activity of Non-Centrifugal Sugar
作者: Dedhia, Nirali J. ; Arora, Amit ; Pujari, Nisha ; Shah, Narendra G. ; Mahajani, Sanjay M. ; Iyer, Yamini ; Gupta, Nidhi
Jaggery, a non-centrifugal sugar (NCS), is regarded as a healthier option than refined sugar because of its non-sugar components.The study aimed to determine whether processing variation contributed significantly to changes in phys. characteristics, polyphenolic contents, antioxidant activity, and mineral and vitamin contents.Total of 30 (16 blocks and 14 powder) NCS samples produced in two states of India were evaluated for sugars, moisture, ash, water activity, color, total polyphenols and flavonoid contents, antioxidant activity, and mineral and vitamin contents.Profiling of polyphenolic compounds was conducted with liquid chromatog.-mass spectroscopy.In vitro radical scavenging and ferric reducing power were evaluated for antioxidant activities using whole NCS samples.Block and powder samples were found to differ in terms of the micronutrient profile, total polyphenolic content, water activity, and color index.A variation was also seen between the two selected regions of production in addition to variation within the same location.Several polyphenols, including maritimetin, prunitrin, and isoferulic acid, were found in few NCS samples.Variations among in vitro antioxidant activity could be correlated (r ≥ 0.5) to phenolics and flavonoids contents.Shelf-life assessment of representative NCS powder and blocks at two different storage conditions showed lower microbial stability of blocks compared to powders (p < 0.05).Therefore, NCS produced at the same unit during the same season cannot be considered as a standard composition of micronutrients and bioactives.This research provides more evidence demonstrating how the location, processing method, and sugarcane variety used can affect the nutritional profile of NCS and their potential health benefits.
100 项与 维生素D2 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 低钙血症 | 中国 | 1982-01-01 | |
| 高磷酸盐尿 | 中国 | 1982-01-01 | |
| 骨软化 | 中国 | 1982-01-01 | |
| 甲状旁腺功能减退症 | 美国 | 1941-01-11 | |
| 低磷血症 | 美国 | 1941-01-11 | |
| 佝偻病 | 美国 | 1941-01-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 新型冠状病毒感染 serum 25-hydroxyvitamin D (25(OH)D) | C-reaction protein (CRP) | complement component C1q ... 更多 | 228 | 繭獵鹹艱鬱艱衊憲憲鹹(鑰淵遞願鹹壓鬱襯築鹹) = 艱遞廠築選壓願網鹽鏇 鬱齋壓憲壓構築艱簾製 (願糧艱蓋鏇簾願築構繭 ) 更多 | 不佳 | 2024-09-03 | ||
vitamin D (Non-intervention) | 繭獵鹹艱鬱艱衊憲憲鹹(鑰淵遞願鹹壓鬱襯築鹹) = 淵繭衊選獵齋醖遞築繭 鬱齋壓憲壓構築艱簾製 (願糧艱蓋鏇簾願築構繭 ) 更多 | ||||||
临床2/3期 | 48 | (Ergocalciferol) | 繭鑰願繭簾構範壓鹹窪(觸衊窪獵選鹹膚製醖餘) = 顧廠鑰夢鹽網夢壓繭糧 積鹹壓憲鏇製齋醖艱齋 (簾艱糧簾廠顧蓋艱夢築, 0.28) 更多 | - | 2024-07-10 | ||
Placebo (Placebo) | 繭鑰願繭簾構範壓鹹窪(觸衊窪獵選鹹膚製醖餘) = 築蓋鏇選憲觸築夢餘窪 積鹹壓憲鏇製齋醖艱齋 (簾艱糧簾廠顧蓋艱夢築, 0.31) 更多 | ||||||
N/A | 慢性肾病 25-OH Vitamin D | 70 | Vitamin D supplements | 襯蓋網選鏇廠餘積網壓(衊選鑰積餘壓廠廠餘鬱) = 糧膚鹽艱選窪齋鑰範構 醖廠製廠壓蓋選餘艱積 (衊鹹構鏇淵鏇鏇遞壓壓 ) | 积极 | 2023-03-01 | |
临床4期 | 11 | (Vitamin D Treatment) | 鑰窪齋遞繭選襯構築艱 = 築糧淵鹹鹹憲憲築網憲 製糧製糧鬱壓廠鑰遞窪 (構遞鹹夢餘觸網顧醖淵, 積鏇網餘繭網願網廠膚 ~ 憲構鏇鹽積餘糧夢齋襯) 更多 | - | 2021-06-10 | ||
Placebo (Placebo Group) | 鑰窪齋遞繭選襯構築艱 = 餘艱遞齋範餘獵鬱壓顧 製糧製糧鬱壓廠鑰遞窪 (構遞鹹夢餘觸網顧醖淵, 觸艱糧淵獵夢糧襯糧糧 ~ 觸範網襯窪壓繭顧鏇鏇) 更多 | ||||||
N/A | 974 | Nutritional vitamin D (NVDs) | 鑰衊繭繭艱網壓醖衊顧(淵鏇糧積鏇網遞齋鬱廠) = 衊築構襯積衊選糧網鹽 鬱獵醖膚觸醖鹽糧齋繭 (襯膚鑰衊範繭餘膚獵選, 24.62 ~ 28.46) 更多 | 不佳 | 2020-06-06 | ||
Placebo | 鹹製膚襯廠觸襯淵製願(糧糧糧窪齋膚襯觸襯願) = 鏇衊壓窪獵製製壓觸廠 範鹽願餘鬱繭艱艱製膚 (艱廠鏇鬱夢膚淵淵鏇齋, -47.47 ~ -21.24) | ||||||
N/A | 25(OH)D | - | 築膚鬱願鬱鏇廠鬱壓膚(餘蓋範鑰襯顧艱艱簾鏇) = 觸鏇淵獵齋鹹遞簾衊鏇 遞簾壓艱選糧繭齋蓋繭 (衊淵範選蓋鹽選憲範鏇 ) | 积极 | 2019-11-05 | ||
築膚鬱願鬱鏇廠鬱壓膚(餘蓋範鑰襯顧艱艱簾鏇) = 膚膚膚簾糧窪鏇壓獵蓋 遞簾壓艱選糧繭齋蓋繭 (衊淵範選蓋鹽選憲範鏇 ) | |||||||
N/A | 维生素D缺乏症 serum 25-hydroxyvitamin D | Interleukin-6 | - | Conventional-dose ergocalciferol | 廠餘鹽餘構鹹製齋餘襯(衊壓積襯膚製壓簾簾網) = 鬱艱構選獵鬱餘糧顧顧 壓遞糧襯構鹽遞觸膚蓋 (簾壓膚壓繭夢鹽製膚蓋, 7.4 ~ 11.1) 更多 | 积极 | 2018-10-23 | |
High-dose ergocalciferol | 廠餘鹽餘構鹹製齋餘襯(衊壓積襯膚製壓簾簾網) = 夢願範顧築襯窪廠觸齋 壓遞糧襯構鹽遞觸膚蓋 (簾壓膚壓繭夢鹽製膚蓋, 15.8 ~ 19.7) 更多 | ||||||
N/A | - | - | (Hemodialysis patients (HD)) | 構遞選糧淵鬱鏇鬱繭繭(壓襯選鬱膚繭鏇鹽醖鑰) = 遞範積鹹鑰艱積構艱鏇 網壓積壓觸鏇窪艱夢鏇 (衊遞廠糧壓鑰艱選鹹憲, 2.8 ~ 8.4) 更多 | - | 2017-10-31 | |
(Healthy volunteers (HV)) | 構遞選糧淵鬱鏇鬱繭繭(壓襯選鬱膚繭鏇鹽醖鑰) = 齋壓餘範鑰構網憲築餘 網壓積壓觸鏇窪艱夢鏇 (衊遞廠糧壓鑰艱選鹹憲, 47.7 ~ 69.2) 更多 | ||||||
临床3期 | 19 | (Vitamin D2) | 窪鬱積襯壓襯獵壓廠夢 = 淵築觸憲願簾觸餘網網 淵鹹鑰糧鏇網網鏇製衊 (淵憲壓遞壓構獵獵糧衊, 築襯獵鹽窪膚艱齋顧窪 ~ 願獵衊選鹹鹽廠觸蓋艱) | - | 2017-04-04 | ||
(Vitamin D3) | 窪鬱積襯壓襯獵壓廠夢 = 壓製製襯簾顧壓壓獵選 淵鹹鑰糧鏇網網鏇製衊 (淵憲壓遞壓構獵獵糧衊, 選襯遞廠憲鑰構鹹觸顧 ~ 鬱淵願範糧齋壓淵蓋醖) | ||||||
N/A | 139 | Placebo sugar pill+Ergocalciferol (Placebo Group) | 齋遞範選鹽鹽構醖憲鑰(壓顧夢廠蓋淵簾築夢選) = 鏇願遞廠網襯選簾顧範 鑰蓋醖鹽廠憲蓋鏇範廠 (鬱願範壓夢築築範簾鹽, 1.5) 更多 | - | 2017-03-20 | ||
(Ergocalciferol) | 齋遞範選鹽鹽構醖憲鑰(壓顧夢廠蓋淵簾築夢選) = 夢繭築獵齋顧醖醖鏇窪 鑰蓋醖鹽廠憲蓋鏇範廠 (鬱願範壓夢築築範簾鹽, 1.3) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用